Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Roberts

Showing results (171-180 of 189) with videos related to

Pageof 19
Sort By:
Plos One|March 4, 2021
Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasmaFor Yue Tso, Salum J Lidenge, Lisa K Poppe, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2021
Transcriptome and Functions of Granulocytic Myeloid-Derived Suppressor Cells Determine their Association with Disease Severity of COVID-19Matthew J Dean, Juan B Ochoa, Maria Sanchez-Pino, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2017
Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase αPriya Kishnani, Mark Tarnopolsky, Mark Roberts, et al.
Plos Pathogens|August 31, 2011
Salmonella bongori provides insights into the evolution of the SalmonellaeMaria Fookes, Gunnar N Schroeder, Gemma C Langridge, et al.
Journal of Neurology|August 16, 2025
Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trialPriya S Kishnani, Jordi Díaz-Manera, Sergey Illarioshkin, et al.
European Journal of Neurology|June 14, 2024
Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024Benedikt Schoser, Nadine A M E van der Beek, Alexander Broomfield, et al.
Human Mutation|April 5, 2012
Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathiesAndrea Klein, Suzanne Lillis, Iulia Munteanu, et al.
Frontiers in Immunology|August 3, 2021
Severe COVID-19 Is Characterized by an Impaired Type I Interferon Response and Elevated Levels of Arginase Producing Granulocytic Myeloid Derived Suppressor CellsMatthew J Dean, Juan B Ochoa, Maria Dulfary Sanchez-Pino, et al.
JAMA Neurology|April 10, 2023
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical TrialPriya S Kishnani, Jordi Diaz-Manera, Antonio Toscano, et al.
Annals of Neurology|June 13, 2019
Pathogenic variants in MT-ATP6: A United Kingdom-based mitochondrial disease cohort studyYi Shiau Ng, Mika H Martikainen, Gráinne S Gorman, et al.
Pageof 19

Showing results (171-180 of 189) with videos related to

Sort By:
Pageof 19
Plos One|March 4, 2021
Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasmaFor Yue Tso, Salum J Lidenge, Lisa K Poppe, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2021
Transcriptome and Functions of Granulocytic Myeloid-Derived Suppressor Cells Determine their Association with Disease Severity of COVID-19Matthew J Dean, Juan B Ochoa, Maria Sanchez-Pino, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2017
Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase αPriya Kishnani, Mark Tarnopolsky, Mark Roberts, et al.
Plos Pathogens|August 31, 2011
Salmonella bongori provides insights into the evolution of the SalmonellaeMaria Fookes, Gunnar N Schroeder, Gemma C Langridge, et al.
Journal of Neurology|August 16, 2025
Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trialPriya S Kishnani, Jordi Díaz-Manera, Sergey Illarioshkin, et al.
European Journal of Neurology|June 14, 2024
Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024Benedikt Schoser, Nadine A M E van der Beek, Alexander Broomfield, et al.
Human Mutation|April 5, 2012
Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathiesAndrea Klein, Suzanne Lillis, Iulia Munteanu, et al.
Frontiers in Immunology|August 3, 2021
Severe COVID-19 Is Characterized by an Impaired Type I Interferon Response and Elevated Levels of Arginase Producing Granulocytic Myeloid Derived Suppressor CellsMatthew J Dean, Juan B Ochoa, Maria Dulfary Sanchez-Pino, et al.
JAMA Neurology|April 10, 2023
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical TrialPriya S Kishnani, Jordi Diaz-Manera, Antonio Toscano, et al.
Annals of Neurology|June 13, 2019
Pathogenic variants in MT-ATP6: A United Kingdom-based mitochondrial disease cohort studyYi Shiau Ng, Mika H Martikainen, Gráinne S Gorman, et al.
Pageof 19